@article{santarpia_correlation_2017,
	title = {Correlation of {DNA} {Repair} {Gene} {Polymorphisms} {With} {Clinical} {Outcome} in {Patients} {With} {Locally} {Advanced} {Non}-{Small}-{Cell} {Lung} {Cancer} {Receiving} {Induction} {Chemotherapy} {Followed} by {Surgery}},
	volume = {18},
	issn = {1938-0690},
	doi = {10.1016/j.cllc.2016.08.007},
	abstract = {OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery.
MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival.
RESULTS: The median survival was 32.14 months for carriers of XPD 312 Asp/Asp and 12.04 months for those with the variant Asn allele (P = .05). In addition, event-free survival was longer for patients with the XPD 312 Asp/Asp genotype compared with patients with Asp/Asn or Asn/Asn (P = .03). A similar but nonsignificant trend was observed for the XPD 751 genotype. In a multivariate analysis, complete resection and age emerged as prognostic factors for overall survival; in patients with incomplete resection or exploratory thoracotomy, XPD 312 was the most significant prognostic factor (P = .03).
CONCLUSION: The XPD 312 single nucleotide polymorphism is a prognostic factor for survival in patients with locally advanced NSCLC receiving induction chemotherapy followed by surgery. The Asn allele is associated with unfavorable outcome and could be used for better stratification of patients.},
	language = {eng},
	number = {2},
	journal = {Clinical Lung Cancer},
	author = {Santarpia, Mariacarmela and Ramirez, Jose Luis and de Aguirre, Itziar and Garrido, Pilar and Pérez Cano, Maria and Queralt, Cristina and Gonzalez-Larriba, Jose Luis and Insa, Amelia and Provencio, Mariano and Isla, Dolores and Camps, Carlos and Blanco, Remei and Moran, Teresa and Rosell, Rafael and {Spanish Lung Cancer Group}},
	year = {2017},
	pmid = {27908619},
	keywords = {Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Article, Biomarkers, Tumor, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Deoxycytidine, Female, Follow-Up Studies, Genotype, Humans, Immunoenzyme Techniques, Induction Chemotherapy, Locally advanced non-small cell lung cancer (NSCLC), Lung Neoplasms, Male, Middle Aged, Neoadjuvant chemotherapy, Neoplasm Staging, Oncologia, Polymorphism, Single Nucleotide, Prognosis, Prospective Studies, Ribonucleotide reductase subunit M1 (RRM1), Single nucleotide polymorphisms (SNPs), Survival Rate, Taxoids, Tumor Suppressor Proteins, Xeroderma Pigmentosum Group D Protein, Xeroderma pigmentosum group D (XPD)},
	pages = {178--188.e4},
}

{"_id":"nirRyRrZDRAWr2QbT","bibbaseid":"santarpia-ramirez-deaguirre-garrido-prezcano-queralt-gonzalezlarriba-insa-etal-correlationofdnarepairgenepolymorphismswithclinicaloutcomeinpatientswithlocallyadvancednonsmallcelllungcancerreceivinginductionchemotherapyfollowedbysurgery-2017","downloads":0,"creationDate":"2018-10-11T03:50:31.467Z","title":"Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery","author_short":["Santarpia, M.","Ramirez, J. L.","de Aguirre, I.","Garrido, P.","Pérez Cano, M.","Queralt, C.","Gonzalez-Larriba, J. L.","Insa, A.","Provencio, M.","Isla, D.","Camps, C.","Blanco, R.","Moran, T.","Rosell, R.","Spanish Lung Cancer Group"],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery","volume":"18","issn":"1938-0690","doi":"10.1016/j.cllc.2016.08.007","abstract":"OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival. RESULTS: The median survival was 32.14 months for carriers of XPD 312 Asp/Asp and 12.04 months for those with the variant Asn allele (P = .05). In addition, event-free survival was longer for patients with the XPD 312 Asp/Asp genotype compared with patients with Asp/Asn or Asn/Asn (P = .03). A similar but nonsignificant trend was observed for the XPD 751 genotype. In a multivariate analysis, complete resection and age emerged as prognostic factors for overall survival; in patients with incomplete resection or exploratory thoracotomy, XPD 312 was the most significant prognostic factor (P = .03). CONCLUSION: The XPD 312 single nucleotide polymorphism is a prognostic factor for survival in patients with locally advanced NSCLC receiving induction chemotherapy followed by surgery. The Asn allele is associated with unfavorable outcome and could be used for better stratification of patients.","language":"eng","number":"2","journal":"Clinical Lung Cancer","author":[{"propositions":[],"lastnames":["Santarpia"],"firstnames":["Mariacarmela"],"suffixes":[]},{"propositions":[],"lastnames":["Ramirez"],"firstnames":["Jose","Luis"],"suffixes":[]},{"propositions":["de"],"lastnames":["Aguirre"],"firstnames":["Itziar"],"suffixes":[]},{"propositions":[],"lastnames":["Garrido"],"firstnames":["Pilar"],"suffixes":[]},{"propositions":[],"lastnames":["Pérez","Cano"],"firstnames":["Maria"],"suffixes":[]},{"propositions":[],"lastnames":["Queralt"],"firstnames":["Cristina"],"suffixes":[]},{"propositions":[],"lastnames":["Gonzalez-Larriba"],"firstnames":["Jose","Luis"],"suffixes":[]},{"propositions":[],"lastnames":["Insa"],"firstnames":["Amelia"],"suffixes":[]},{"propositions":[],"lastnames":["Provencio"],"firstnames":["Mariano"],"suffixes":[]},{"propositions":[],"lastnames":["Isla"],"firstnames":["Dolores"],"suffixes":[]},{"propositions":[],"lastnames":["Camps"],"firstnames":["Carlos"],"suffixes":[]},{"propositions":[],"lastnames":["Blanco"],"firstnames":["Remei"],"suffixes":[]},{"propositions":[],"lastnames":["Moran"],"firstnames":["Teresa"],"suffixes":[]},{"propositions":[],"lastnames":["Rosell"],"firstnames":["Rafael"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Spanish Lung Cancer Group"],"suffixes":[]}],"year":"2017","pmid":"27908619","keywords":"Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Article, Biomarkers, Tumor, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Deoxycytidine, Female, Follow-Up Studies, Genotype, Humans, Immunoenzyme Techniques, Induction Chemotherapy, Locally advanced non-small cell lung cancer (NSCLC), Lung Neoplasms, Male, Middle Aged, Neoadjuvant chemotherapy, Neoplasm Staging, Oncologia, Polymorphism, Single Nucleotide, Prognosis, Prospective Studies, Ribonucleotide reductase subunit M1 (RRM1), Single nucleotide polymorphisms (SNPs), Survival Rate, Taxoids, Tumor Suppressor Proteins, Xeroderma Pigmentosum Group D Protein, Xeroderma pigmentosum group D (XPD)","pages":"178–188.e4","bibtex":"@article{santarpia_correlation_2017,\n\ttitle = {Correlation of {DNA} {Repair} {Gene} {Polymorphisms} {With} {Clinical} {Outcome} in {Patients} {With} {Locally} {Advanced} {Non}-{Small}-{Cell} {Lung} {Cancer} {Receiving} {Induction} {Chemotherapy} {Followed} by {Surgery}},\n\tvolume = {18},\n\tissn = {1938-0690},\n\tdoi = {10.1016/j.cllc.2016.08.007},\n\tabstract = {OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery.\nMATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival.\nRESULTS: The median survival was 32.14 months for carriers of XPD 312 Asp/Asp and 12.04 months for those with the variant Asn allele (P = .05). In addition, event-free survival was longer for patients with the XPD 312 Asp/Asp genotype compared with patients with Asp/Asn or Asn/Asn (P = .03). A similar but nonsignificant trend was observed for the XPD 751 genotype. In a multivariate analysis, complete resection and age emerged as prognostic factors for overall survival; in patients with incomplete resection or exploratory thoracotomy, XPD 312 was the most significant prognostic factor (P = .03).\nCONCLUSION: The XPD 312 single nucleotide polymorphism is a prognostic factor for survival in patients with locally advanced NSCLC receiving induction chemotherapy followed by surgery. The Asn allele is associated with unfavorable outcome and could be used for better stratification of patients.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Clinical Lung Cancer},\n\tauthor = {Santarpia, Mariacarmela and Ramirez, Jose Luis and de Aguirre, Itziar and Garrido, Pilar and Pérez Cano, Maria and Queralt, Cristina and Gonzalez-Larriba, Jose Luis and Insa, Amelia and Provencio, Mariano and Isla, Dolores and Camps, Carlos and Blanco, Remei and Moran, Teresa and Rosell, Rafael and {Spanish Lung Cancer Group}},\n\tyear = {2017},\n\tpmid = {27908619},\n\tkeywords = {Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Article, Biomarkers, Tumor, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Deoxycytidine, Female, Follow-Up Studies, Genotype, Humans, Immunoenzyme Techniques, Induction Chemotherapy, Locally advanced non-small cell lung cancer (NSCLC), Lung Neoplasms, Male, Middle Aged, Neoadjuvant chemotherapy, Neoplasm Staging, Oncologia, Polymorphism, Single Nucleotide, Prognosis, Prospective Studies, Ribonucleotide reductase subunit M1 (RRM1), Single nucleotide polymorphisms (SNPs), Survival Rate, Taxoids, Tumor Suppressor Proteins, Xeroderma Pigmentosum Group D Protein, Xeroderma pigmentosum group D (XPD)},\n\tpages = {178--188.e4},\n}\n\n","author_short":["Santarpia, M.","Ramirez, J. L.","de Aguirre, I.","Garrido, P.","Pérez Cano, M.","Queralt, C.","Gonzalez-Larriba, J. L.","Insa, A.","Provencio, M.","Isla, D.","Camps, C.","Blanco, R.","Moran, T.","Rosell, R.","Spanish Lung Cancer Group"],"key":"santarpia_correlation_2017","id":"santarpia_correlation_2017","bibbaseid":"santarpia-ramirez-deaguirre-garrido-prezcano-queralt-gonzalezlarriba-insa-etal-correlationofdnarepairgenepolymorphismswithclinicaloutcomeinpatientswithlocallyadvancednonsmallcelllungcancerreceivinginductionchemotherapyfollowedbysurgery-2017","role":"author","urls":{},"keyword":["Adenocarcinoma","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Article","Biomarkers","Tumor","Carcinoma","Large Cell","Carcinoma","Non-Small-Cell Lung","Carcinoma","Squamous Cell","Cisplatin","Combined Modality Therapy","Deoxycytidine","Female","Follow-Up Studies","Genotype","Humans","Immunoenzyme Techniques","Induction Chemotherapy","Locally advanced non-small cell lung cancer (NSCLC)","Lung Neoplasms","Male","Middle Aged","Neoadjuvant chemotherapy","Neoplasm Staging","Oncologia","Polymorphism","Single Nucleotide","Prognosis","Prospective Studies","Ribonucleotide reductase subunit M1 (RRM1)","Single nucleotide polymorphisms (SNPs)","Survival Rate","Taxoids","Tumor Suppressor Proteins","Xeroderma Pigmentosum Group D Protein","Xeroderma pigmentosum group D (XPD)"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["correlation","dna","repair","gene","polymorphisms","clinical","outcome","patients","locally","advanced","non","small","cell","lung","cancer","receiving","induction","chemotherapy","followed","surgery","santarpia","ramirez","de aguirre","garrido","pérez cano","queralt","gonzalez-larriba","insa","provencio","isla","camps","blanco","moran","rosell","spanish lung cancer group"],"keywords":["adenocarcinoma","adult","aged","antineoplastic combined chemotherapy protocols","article","biomarkers","tumor","carcinoma","large cell","carcinoma","non-small-cell lung","carcinoma","squamous cell","cisplatin","combined modality therapy","deoxycytidine","female","follow-up studies","genotype","humans","immunoenzyme techniques","induction chemotherapy","locally advanced non-small cell lung cancer (nsclc)","lung neoplasms","male","middle aged","neoadjuvant chemotherapy","neoplasm staging","oncologia","polymorphism","single nucleotide","prognosis","prospective studies","ribonucleotide reductase subunit m1 (rrm1)","single nucleotide polymorphisms (snps)","survival rate","taxoids","tumor suppressor proteins","xeroderma pigmentosum group d protein","xeroderma pigmentosum group d (xpd)"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}